

WORLD JOURNAL OF PHARMACEUTICAL RESEARCH

SJIF Impact Factor 8.453

Volume 14, Issue 4, 59-77.

Review Article

ISSN 2277-7105

ADVANCED METHOD OF IMMUNOLOGICAL DISEASE DIAGNOSIS

*¹Sanskruti Banduji Gudadhe, ²Pranita P. Zodape, Prof. Vishnudas K. Lokhande, Dr. Rahul S. Bijwar and Dr. Laxmikant N. Barde

Jagadambha Institute of Pharmacy & Research, Kalamb.

Article Received on 01 January 2025, Revised on 21 Jan. 2024, Accepted on 10 Feb. 2025 DOI: 10.20959/wjpr20254-34923



*Corresponding Author
Sanskruti Banduji Gudadhe
Jagadambha Institute of
Pharmacy & Research,
Kalamb.

ABSTRACT

The advanced diagnosis of immunological diseases has significantly evolved with the integration of cutting-edge technologies, enhancing precision, speed, and accuracy in detecting immune system dysfunctions. These methods leverage molecular diagnostics, highthroughput sequencing, bioinformatics, and imaging technologies to identify biomarkers, genetic predispositions, and immune response anomalies. Techniques such flow cytometry, as multiplex immunoassays, next-generation sequencing (ngs), and machine learning-based diagnostic tools enable a comprehensive understanding of the immune landscape. Moreover, the application of omics approaches, including proteomics and transcriptomics, provides insights into disease mechanisms and personalized medicine. This review highlights the advancements in diagnostic techniques, their

clinical implications, and the challenges in implementing them in routine clinical practice, emphasizing their role in improving patient outcomes for immunological diseases.

KEYWORDS: Immunological diseases, advanced diagnostics, flow cytometry, multiplex immunoassays, next-generation sequencing (ngs), biomarkers, omics technologies, machine learning, personalized medicine.

1. INTRODUCTION

Immunological disease diagnosis is a method of detecting immunological diseases by using the body's natural response to pathogens and antigens.

Immunological disease diagnosis involves identifying diseases that are related to the immune system. These conditions may occur when the immune system functions improperly, such as

www.wjpr.net Vol 14, Issue 4, 2025. ISO 9001: 2015 Certified Journal 59

in autoimmune diseases (where the body attacks itself) or immunodeficiency diseases (where the immune system is underactive). The diagnosis of immunological diseases requires careful evaluation through clinical examination, laboratory tests, and sometimes genetic testing. Here is a breakdown of the main aspects of immunological disease diagnosis.

The immune system's primary role is to defend the body against harmful pathogens like bacteria, viruses, and parasites, as well as to detect and eliminate abnormal cells. However, in immunological diseases, this system can malfunction, leading to conditions such as autoimmune diseases, hypersensitivities, immunodeficiencies, and other immune-related disorders.

Immunochemistry offers simple, rapid, robust yet sensitive, and in most cases, easily automated methods applicable to routine analyses in clinical laboratories Similarly, immunohistochemistry, one of the main diagnostics tools in today's clinical laboratories, is also based on the principles of antigen-antibody binding.^[1]

Currently, the support of the laboratory in the diagnosis of autoimmune diseases is due to a large number of techniques that allow both to identify and confirm, or recognize specific antigen(s). Moreover, such techniques have evolved considerably in recent decades, as tests have been developed with greater specificity and sensitivity. Among the most used techniques are: indirect immunofluorescence (IFI), immunosorbent assay (ELISA), the multiplex assay and electroimmuno transference (EIT).^[2]

Autoimmune diseases (AIDs) are a series of serious events which take place in the human body due to internal and external factors leading to the immune system could not discriminate between self and nonself of specific antigens followed by simple, mild, and severe deterioration in targeted tissue/orga.^[3]

2. ASSAY

A structured explanation of immunological assays commonly used in diagnosing immunological diseases. [4]

- 1. Types of Immunological Assays
- 2. Overview of Immunological Disease Diagnosis
- 3. Applications in Immunological Disease Diagnosis
- 4. Advantages and Limitations of Immunological Assays

2.1. Types of Immunological Assays

Immunological assays are techniques used to identify and quantify the presence of antibodies, antigens, or immune cells involved in immune responses. Some common assays include:

• Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA is used to detect antibodies or antigens in a sample by binding them to an enzymelinked antibody.

Steps

- i. A plate is coated with an antigen or antibody.
- ii. The patient's sample is added, and any antibodies present bind to the antigen.
- iii. A secondary enzyme-linked antibody is added that binds specifically to the target.
- iv. A substrate is added, causing a color change if binding has occurred.

Example Use Detecting antibodies against pathogens like HIV or autoimmune antibodies in diseases like lupus.

• Flow Cytometry

Flow cytometry detects and measures physical and chemical properties of cells, including immune cells, in a fluid sample.

Steps

- i. Cells are tagged with fluorescent antibodies specific to particular cell markers.
- ii. The sample passes through a laser, and the light scatter and fluorescence data identify cell types.

Example Use Diagnosing immunodeficiencies by quantifying T cells, B cells, and other immune cells.

Western Blot

Western blot identifies specific proteins (e.g., antibodies or antigens) in a patient sample.

Steps:

- i. Proteins are separated by size using gel electrophoresis.
- ii. They are transferred to a membrane, then detected with antibodies.
- iii. A secondary enzyme-linked antibody and substrate reveal bands corresponding to the target protein.

Example Use Confirming HIV diagnosis after ELISA.

• Immunofluorescence Assay (IFA)

IFA uses fluorescent antibodies to detect antigens in a tissue or cell sample.

Steps

- i. The sample is incubated with antibodies specific to the target antigen.
- ii. A fluorescently labeled secondary antibody is added.
- ii. The sample is visualized under a fluorescence microscope.

Example Use Diagnosing autoimmune diseases by detecting specific antibodies.

• Radioimmunoassay (RIA)

RIA is used to measure antigen-antibody reactions using radioactive labels.

Steps

- i. The patient's sample is mixed with a radioactive antigen and an antibody.
- ii. Radioactivity levels are measured to quantify binding.

Example Use Hormone level measurement, such as insulin in diabetes.

2.2. Overview of Immunological Disease Diagnosis

Immunological diseases are conditions where the immune system malfunctions, either attacking the body's own tissues (autoimmune diseases) or failing to protect against infections (immunodeficiency).

Accurate diagnosis of these diseases is essential for effective treatment, and immunological assays provide a means of detecting these abnormalities.

2.3. Applications in Immunological Disease Diagnosis

Immunological assays are used to diagnose a wide range of conditions, including:

- **a.) Autoimmune Diseases:** Tests for autoantibodies are essential for diagnosing conditions like rheumatoid arthritis or lupus.^[6]
- **b) Immunodeficiencies:** Flow cytometry can assess immune cell counts in conditions like HIV/AIDS or severe combined immunodeficiency (SCID).

- c) Allergies: ELISA can measure levels of specific immunoglobulin E (IgE) antibodies that indicate allergies.^[5]
- **d) Infectious Diseases:** Assays can detect antibodies against infectious agents, useful in diagnosing conditions such as hepatitis, tuberculosis, or syphilis.

2.4. Advantages and Limitations of Immunological Assays

• Advantages:

- 1. High specificity and sensitivity in detecting immune responses.
- 2. Some assays, like ELISA, are easy to automate and can process many samples.

• Limitations:

- 1. Some assays may produce false positives/negatives.
- 2. Certain methods require advanced lab facilities and trained personnel.

3. OBJECTIVES

The main objectives in managing immunological disorders—ranging from autoimmune diseases to immunodeficiencies—include early detection, controlling disease progression, improving patient quality of life, and ultimately achieving disease remission or management. Here's a breakdown of these key objectives:

3.1. Early Detection and Diagnosis

- **Objective** Identify immunological disorders as early as possible to prevent disease progression and enable prompt intervention.
- **Approach** Early detection involves screening individuals at high risk, such as those with a family history of autoimmune disorders, or using biomarker-based diagnostic tools.^[7]

3.2. Control of Disease Progression

- **Objective** Limit the spread of autoimmune attacks or minimize immunodeficiency-related infections to reduce long-term complications.
- Approach Immunosuppressive therapies, biologics, and targeted medications are often
 used to slow the immune system's overactivity in autoimmune diseases. For
 immunodeficiencies, infection prevention measures, vaccinations, and immune globulin
 replacement can help prevent recurrent infections.^[8]

3.3. Improvement of Quality of Life

- **Objective** Alleviate symptoms and maintain functional capacity, allowing patients to lead normal lives despite their condition.
- **Approach** Treatments are tailored to manage symptoms such as fatigue, pain, and inflammation, along with lifestyle adjustments, counseling, and support. [9]

3.4. Prevention of Complications And Comorbidities

- Objective Minimize the risk of complications that arise from either the disease itself or
 its treatment, including infections, organ damage, and secondary conditions like
 cardiovascular disease.
- Approach Regular monitoring and proactive management strategies, such as cardiovascular screening for autoimmune patients, are essential to detect and manage comorbidities early.^[10]

3.5. Achieving and Maintaining Disease Remission or Stability

- **Objective** Induce remission or at least maintain disease stability to prevent relapses and improve long-term outcomes.
- **Approach** Maintenance therapies are often prescribed, especially in cases where disease-modifying treatments have been effective in inducing remission. Monitoring biomarkers can help in adjusting treatments to prevent flare-ups. [11]

3.6. Advancement of Research for Future Therapies

- **Objective** Continuously advance understanding and treatment options to achieve more effective and safer therapies.
- Approach Clinical trials, genetic studies, and research into new therapeutic agents, such
 as biologics and gene therapies, are crucial for long-term progress in treating
 immunological disorders.^[12]

4. IMMUNOLOGICAL METHODS

Immunological disease diagnosis involves various methods that help identify immune system disorders. Here are some of the primary methods used for diagnosis, along with references for further reading:

• **TECHNIQES:-** S. No. Techniques Application to diagnosis immunological disease.

1. Serological tests

- 2. Flow Cytometry
- 3. Lymphocyte Proliferation Assays
- 4. Immunohistochemistry (IHC)
- 5. Genetic Testing
- 6. Skin Tests
- 7. Enzyme assays
- 8. Next-generation sequencing (NGS)
- 9. CRISPR/Cas system
- 10. Mass spectrometry (MS/MS)
- 11. PCR-based immunodetection
- 12. Metagenomics (panpathogen metagenomic sequencing assay)
- 13. Immunosensors (sandwich-type electrochemiluminescence (ECL) immunosensor)
- 15. miRNA-based immunodetection
- **4.1. Serological Tests Description**: These tests detect antibodies or antigens in the blood. Common serological tests include enzyme-linked immunosorbent assays (ELISAs), Western blotting, and immunofluorescence assays.

Application: Useful in diagnosing autoimmune diseases (e.g., rheumatoid arthritis, lupus) and infectinos.^[13]

4.2. Flow Cytometry

Description: This technique analyzes the physical and chemical characteristics of cells or particles. It can quantify different immune cell types, their activation states, and the presence of specific surface markers.

Application: Essential for diagnosing hematological malignancies and monitoring immune status in various diseases.^[14]

4.3. Lymphocyte Proliferation Assays

Description: These tests measure the ability of lymphocytes to proliferate in response to specific antigens or mitogens.

Application: Helps assess immune function in conditions like immunodeficiency or autoimmune diseases. [15]

4.4. Immunohistochemistry (IHC)

Description: A technique used to identify specific antigens in cells or tissue sections using labeled antibodies.

Application: Often used in the diagnosis of cancers and autoimmune diseases by examining tissue samples.^[16]

4.5. Genetic Testing Description: Analysis of genetic material to identify mutations associated with immunological disorders, such as primary immunodeficiencies.

Application: Important for diagnosing hereditary immune system disorders.^[17]

4.6. Skin Tests

Description: Tests such as the tuberculin skin test or patch tests assess immune responses to specific antigens.

Application: Useful in diagnosing allergies and certain infections.

4.7. Enzyme Assays

Description: Enzyme assays are laboratory techniques that use enzyme reactions to measure the concentration or activity of specific biomolecules in a sample. In immunological diagnostics, enzymes are often conjugated with antibodies or antigens. The resulting enzymelinked complexes enable the detection of immune markers associated with various diseases.

Application: Used in detecting biomarkers for autoimmune diseases, infectious diseases, allergies, and cancer, enzyme assays are instrumental in understanding the state of the immune system and identifying disease-specific antigens or antibodies.^[37]

4.8. Next-Generation Sequencing (NGS) for Immune Repertoire Analysis

Description: Sequencing of T-cell receptor (TCR) and B-cell receptor (BCR) repertoires to understand immune diversity and clonality.

Applications: Diagnosing lymphoproliferative disorders and tracking minimal residual disease in leukemia. Identifying biomarkers for autoimmune diseases and vaccine responses.

Advantages: High sensitivity and ability to detect rare immune cell clones.

4.9. CRISPR-Based Diagnostic Tools (e.g., SHERLOCK, DETECTR)

Description: Use of CRISPR-Cas systems to detect nucleic acids associated with pathogens or disease biomarkers.

Applications: Rapid detection of infectious diseases (e.g., COVID-19, Zika virus). Identifying genetic mutations linked to immune disorders.

Advantages: Rapid, cost-effective, and adaptable to various diseases.

4.10. Mass Cytometry (CyTOF)

Description: Combines flow cytometry and mass spectrometry to analyze over 40 parameters simultaneously at the single-cell level.

Applications: Immune profiling in complex diseases like multiple sclerosis, HIV/AIDS, and cancers. Monitoring immune cell phenotypes and functions in transplant patients.

Advantages: High dimensionality, providing comprehensive immune insights.

5. IMMNUOLOGICAL DIAGNOSTIC TECHNIQUE OF MEDICAL VIRUS

Immunological diagnostic techniques are essential for detecting and diagnosing viral infections. These techniques leverage the immune response to identify viral antigens or antibodies produced in response to viral infections. Here are some key immunological diagnostic methods used for medical viruses:

5.1. Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA is a widely used technique that detects and quantifies proteins, including viral antigens and antibodies. In this method:

Antigen detection: Patient samples are tested for specific viral antigens using antibodies linked to an enzyme. A substrate is added that produces a measurable signal (color change) when the enzyme reacts, indicating the presence of the virus.




Fig. 1: Enzyme Linked Immunosorbent Assay.

Antibody detection: This variant tests for antibodies in the patient's serum against specific viruses, which indicates a past or current infection.^[18]

5.2. Western Blotting

Western blotting is used to confirm the presence of viral proteins in a sample. The technique involves separating proteins by gel electrophoresis, transferring them to a membrane, and probing with specific antibodies. A visible signal indicates the presence of viral proteins.^[19]

5.3. Immunofluorescence Assay (IFA)

IFA uses fluorescently labeled antibodies to detect viral antigens in infected cells. The sample is treated with antibodies that bind to specific antigens and then examined under a fluorescence microscope. [20]

5.4. Rapid Diagnostic Tests (RDTs)

These are point-of-care tests that provide quick results, often within minutes. RDTs typically utilize lateral flow immunoassays to detect specific viral antigens or antibodies in a sample, such as blood or saliva.^[21]

5.5. Neutralization Tests

This classic method assesses the ability of antibodies in a patient's serum to neutralize a virus in cell culture. The extent of neutralization can indicate the level of immunity or the presence of active infection.^[22]

5.6. Lateral Flow Assays

Lateral flow assays are simple, rapid tests that detect viral proteins or antibodies using a capillary action mechanism. They are often used in at-home testing kits for viral infections.^[23]




Fig. 2: Immunochromatographic Lateral Flow Assay.

6. ANTIBODY GENERATION

Antibody generation is a crucial process in the diagnosis of immunological diseases. It involves producing antibodies that can specifically recognize and bind to antigens associated with these diseases. Here's an overview of the key concepts and methodologies involved in this process:

6. 1. Types of Antibodies

- Monoclonal Antibodies (mAbs): Produced by identical immune cells that are clones of a unique parent cell. They are highly specific to a single epitope.
- Usage: Widely used in diagnostic tests for specific disease markers. [24]
- **Polyclonal Antibodies:** Produced by different B cell lineages in the body. They recognize multiple epitopes on the same antigen, providing a broader response.^[25]
- Usage: Commonly used in serological assays and for research applications.

6.2. Production of Antibodies

- **Immunization:** Animals (commonly mice, rabbits, or goats) are immunized with an antigen related to the disease. This stimulates the animal's immune system to produce antibodies. [26]
- **Hybridoma Technology:** Involves fusing an antibody-producing B cell from an immunized animal with a myeloma (cancer) cell. The resulting hybrid cells (hybridomas) can be screened for those producing the desired antibody. [27]
- **Recombinant Antibodies:** These are engineered using recombinant DNA technology. They can be produced in cell lines without the need for animals. [28]

6.3. Techniques for Antibody Detection

- Enzyme-Linked Immunosorbent Assay (ELISA): A widely used assay to quantify antibodies or antigens in a sample. It involves coating a plate with antigen, adding the sample, and detecting bound antibodies with enzyme-linked secondary antibodies.^[29]
- **Western Blotting:** This technique separates proteins by gel electrophoresis and transfers them to a membrane, where specific antibodies can be used for detection. [30]
- **Immunofluorescence:** Utilizes fluorescently labeled antibodies to visualize the presence and location of specific antigens in tissue samples.^[31]

6.4. Applications in Disease Diagnosis

• **Autoimmune Diseases**: Antibodies can be used to identify autoantibodies associated with diseases like lupus, rheumatoid arthritis, and multiple sclerosis. [32]

- **Infectious Diseases**: Detection of pathogen-specific antibodies can aid in diagnosing infections like HIV, hepatitis, and others.^[33]
- Cancer: Certain tumors express unique antigens that can be targeted by specific antibodies for diagnosis and therapy. [34]

6.5. Future Directions

- **Personalized Medicine:** Development of targeted antibody therapies based on individual immune profiles.^[35]
- **Bispecific Antibodies:** Engineering antibodies that can bind two different antigens, offering more versatile therapeutic and diagnostic options.^[36]
- **Point-of-Care Testing:** Advancements in antibody generation and detection methods are moving towards rapid, on-site diagnostic tests for various immunological diseases. [37]

7. DIAGNOSIS OF TUBERCULOSIS IN NON-BOVID USE IN IMMUNOLOGICAL METHO

Diagnosis of tuberculosis (TB) in non-bovid animals, such as wildlife species or pets, can be challenging, particularly because they may have unique immune responses compared to bovid animals like cattle. Immunological methods are commonly used for TB diagnosis because they detect immune responses specific to Mycobacterium tuberculosis or Mycobacterium bovis, the primary pathogens responsible for tuberculosis. These immunological methods offer various approaches to diagnosing TB in non-bovid animals, helping veterinarians to make informed decisions. Their effectiveness can depend on the species tested and the quality of antigens or reagents used in each test, some immunological methods used for TB diagnosis in non-bovids.

7.1. Tuberculin Skin Test (TST)

• **Explanation:** The Tuberculin Skin Test involves injecting a small amount of purified protein derivative (PPD), a protein extract from Mycobacterium bovis or M. tuberculosis, into the skin. After 48-72 hours, the injection site is observed for swelling, which indicates an immune response if the animal has been exposed to the bacteria. [40]

7.2. Interferon-Gamma Release Assays (IGRAs)

• **Explanation:** IGRAs measure the release of interferon-gamma (IFN-γ), a cytokine produced by T-cells in response to TB antigens. A blood sample from the animal is

exposed to TB antigens, and the amount of IFN- γ produced indicates whether the animal has been exposed to TB.^[41]

7.3. Enzyme-Linked Immunosorbent Assay (ELISA)

• Explanation: ELISA tests detect antibodies against TB in the blood. Specific TB antigens are coated on a plate, and the animal's serum is added. If antibodies specific to TB are present, they bind to the antigens, and a color change occurs, indicating a positive result.^[42]

7.4. Fluorescent Polarization Assay (FPA)

• **Explanation:** FPA detects TB antibodies by measuring the polarization of fluorescent light emitted from TB antigen-antibody complexes. The degree of polarization change helps in identifying TB exposure in the tested animal. [43]

7.5. Polymerase Chain Reaction (PCR) Tests

 Explanation: PCR tests amplify TB-specific DNA sequences directly from blood or tissue samples. While not strictly immunological, PCR can complement immunological tests by confirming the presence of TB DNA.^[44]

7.6. Multi-Antigen Print Immunoassay (MAPIA)

• Explanation: MAPIA is a more advanced immunoassay technique that can simultaneously test for multiple antigens to diagnose TB. It can detect a variety of antibodies, which makes it particularly effective in non-bovid species where antibody responses might vary. [45]

8. Scopes and Importance of Methods for Immunological Disease Diagnosis.

• Scope of Methods in Immunological Disease Diagnosis

Immunological disease diagnosis is crucial for identifying diseases that affect the immune system, including autoimmune diseases, allergies, and immunodeficiencies. Various methods are used to analyze immune response, detect biomarkers, and monitor disease progression.

8.1. Genetic and Molecular Diagnostics:

Genetic and molecular methods, such as PCR (Polymerase Chain Reaction), genetic sequencing, and microarray analysis, enable the identification of genetic mutations or alterations that may predispose individuals to immunological diseases.

Explanation: These methods are used to detect genetic markers associated with conditions like autoimmune diseases, immunodeficiencies, and predisposition to certain infections. [46]

8.2. Flow Cytometry

Flow cytometry is a technique that quantifies and characterizes different cell types, including immune cells, based on surface markers. It is particularly useful for diagnosing immune-related cancers and monitoring immune responses.

Explanation: Flow cytometry provides detailed information about the distribution and function of immune cells, which is essential for diagnosing diseases like leukemia, lymphoma, and monitoring autoimmune disorders.^[47]

8.3. Antibody Detection (ELISA and Western Blot)

Antibody-based assays, such as Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot, help detect the presence of antibodies produced by the immune system in response to infections or autoantigens in autoimmune diseases.

Explanation: These methods help identify specific antibodies associated with autoimmune diseases (e.g., rheumatoid factor in rheumatoid arthritis) or infections (e.g., HIV antibodies).^[48]

8.4. Immunohistochemistry (IHC):

Immunohistochemistry involves using antibodies to detect specific antigens within tissue samples. This method is used to diagnose cancers, autoimmune diseases, and identify immune cell infiltration in tissues.

Explanation: IHC provides spatial localization of immune markers in tissues, helping to diagnose diseases like lupus or cancer-related immune infiltration in organs.^[49]

8.5. Proteomics and Mass Spectrometry

Proteomics, particularly using mass spectrometry, is a method for analyzing proteins expressed in biological samples. It plays a role in identifying biomarkers for immune-related diseases and evaluating the protein profiles of immune cells.

Explanation: Proteomics can provide insights into protein expression changes that occur in autoimmune diseases, cancers, and other immunological disorders, identifying novel biomarkers for diagnosis.^[50]

9. Importance of Methods in Immunological Disease Diagnosis

The importance of advanced methods for immunological disease diagnosis lies in their ability to enhance early detection, provide more accurate diagnoses, and tailor personalized treatments for better outcomes.

9.1. Early Detection and Diagnosis:

Early diagnosis of immunological diseases, often through genetic or molecular tests, enables earlier intervention and more effective treatment before the disease becomes advanced.

Explanation: Early detection of biomarkers or genetic mutations can help prevent irreversible damage, especially in diseases like lupus or rheumatoid arthritis, where early treatment can reduce long-term damage to organs.^[51]

9.2. Personalized Medicine:

With advances in diagnostic methods, clinicians can tailor treatments based on individual genetic profiles and immune system characteristics, ensuring more effective and precise treatment.

Explanation: Personalized approaches allow doctors to select the most suitable therapies based on a patient's immune system's genetic makeup, reducing unnecessary treatments and minimizing side effects.^[52]

9.3. Monitoring Disease Progression:

Advanced diagnostic techniques enable clinicians to monitor the progression of immunological diseases, adjusting treatments based on real-time immune system changes and disease markers.

Explanation: Techniques like flow cytometry and cytokine assays provide valuable data for monitoring autoimmune diseases, enabling more accurate tracking of disease flare-ups or remission.^[53]

9.4. Increased Accuracy and Specificity: Advanced methods improve diagnostic accuracy, offering more reliable results and minimizing the occurrence of false positives and negatives compared to traditional diagnostic techniques.

Explanation: With methods like PCR and immunohistochemistry, the detection of disease markers is more precise, helping doctors diagnose complex immunological diseases with greater confidence.^[54]

9.5. Cost-Effective Disease Management:

By enabling earlier and more accurate diagnoses, advanced immunological diagnostic methods can potentially reduce long-term healthcare costs by preventing unnecessary treatments and hospitalizations.^[55]

CONCLUSION

Advanced methods in immunological disease diagnosis have revolutionized how we detect and monitor immune-related conditions. These techniques, which include flow cytometry, multiplex immunoassays, next-generation sequencing, and advanced imaging, provide precise, sensitive, and comprehensive diagnostic insights. They allow for early detection, accurate differentiation of immune disorders, and personalized treatment approaches. These methods emphasize the integration of molecular and cellular data, enabling a deeper understanding of disease mechanisms. With continuous advancements in technology, such as ai-driven diagnostic tools and single-cell analysis, the future of immunological diagnostics promises even greater specificity and accessibility, paving the way for improved patient outcomes.

REFERENCE

- 1. Frontiers in Immunology, 10, 2828. 1.Marja E. Koivunen, Richard L. Krogsrud (Antibodies Incorporated, Davis, CA) DOI: 10.1309/MV9RM1FDLWAUWQ3F.
- Diego F. Hernández Ramírez and Javier Cabiedes* Laboratorio de Inmunología,
 Departamento de Inmunología y Reumatología, Instituto Nacional de Ciencias Médicas y
 Nutrición Salvador Zubirán, Mexico City, Mexico.
- 3. Mohammed F. Alghamdi & Elrashdy M. Redwan To cite this article: Mohammed F. Alghamdi & Elrashdy M.Redwan (2021): Advances in the diagnosis of autoimmune diseases based on citrullinated peptides/proteins, Expert Review of Molecular Diagnostics, DOI: 10.1080/14737159.2021.1933946 To link to this article: https://doi.org/10.1080/14737159.2021.1933946.
- 4. Parham, P. (2014). The Immune System (4th ed.). Garland Science.
- 5. Janeway, C. A. Jr., Travers, P., Walport, M., & Shlomchik, M. J. (2001). Immunobiology: The Immune System in Health and Disease (5th ed.). Garland Science.
- 6. Davidson, A., & Diamond, B. "Autoimmune Diseases." New England Journal of Medicine, 2020; 382(1): 93-94.

- 7. Walker, B. R., & Colledge, N. R. (2018). Davidson's Principles and Practice of Medicine, 23rd Edition. Elsevier.
- 8. van Middendorp, H., & Geenen, R. "Quality of Life in Patients with Immune-mediated Inflammatory Diseases." Rheumatology, 2019; 58(7): 1191-1193.
- 9. Rosenbaum, J. T., et al. "Comorbidities and Complications in Autoimmune Disease." Journal of Autoimmunity, 2021; 117: 102581.
- 10. Yazdany, J., & Gibofsky, A. "Maintaining Remission in Autoimmune Disease." Nature Reviews Rheumatology, 2021; 17(8): 469-480.
- 11. Firestein, G. S., & McInnes, I. B. "Immunological Mechanisms and Emerging Therapies in Autoimmune Disease." Immunity, 2017; 46(4): 500-513.
- 12. D'Amato, M. et al. "Serological testing in autoimmune diseases." Nature Reviews Rheumatology, 2016; 12(8): 489-500. DOI:10.1038/nrrheum.2016.76.
- 13. Maecker, H. T., & Trotter, J. "Flow cytometry controls." Nature Protocols, 2006; 1(6): 2624-2630. DOI:10.1038/nprot.2006.408.
- 14. Delespesse, G. et al. "Lymphocyte proliferation assays." Method s in Molecular Biology, 2011; 707: 131-142. DOI:10.1007/978-1-61779-000-5 11.
- 15. Ahn, Y. H. et al. "Immunohistochemistry: a review of the technical aspects." Clinical and Experimental Pathology, 2014; 4(1): 25-31.
- 16. Ehl, S. et al. "Genetic Basis of Primary Immunodeficiencies." The Journal of Allergy and Clinical Immunology, 2015; 135(3): 670-678. DOI:10.1016/j.jaci.2014.11.035.
- 17. Rojas, A. et al. "Skin testing: a review of current techniques and applications." Current Allergy and Asthma Reports, 2016; 16(9): 64. DOI:10.1007/s11882-016-0632-0.
- 18. Vashist, A., & Gupta, B. "ELISA: A powerful tool for virus detection." Journal of Immunological Methods, 2018; 469: 41-47.
- 19. Towbin, H., Staehelin, T., & Gordon, J. "Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications." Proceedings of the National Academy of Sciences, 1979; 76(9): 4350-4354.
- 20. Kahn, C. M., & Line, S. "Immunofluorescence techniques for diagnosis of viral diseases." Veterinary Clinics of North America: Small Animal Practice, 2017; 47(4): 707-718.
- 21. Peeling, R. W., et al. "Diagnostics for developing countries." Nature Reviews Microbiology, 2010; 8(3): 212-221.
- 22. Oleru, U. N., & Oyejide, A. "Neutralization tests for the diagnosis of viral infections." Journal of Clinical Microbiology, 1990; 28(11): 2452-2455.

- 23. Roda, A., et al. "Lateral flow tests: A review of the principles and applications." Molecules, 2013; 18(1): 138-157.
- 24. Köhler, G., & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975; 256(5517): 495-497.
- 25. Pabst, R., & Kunkel, E. J. The immune system in the gut: an overview. Clinical and Experimental Immunology, 1993; 92(1): 1-5.
- 26. Harlow, E., & Lane, D. (1988). Antibodies: A Laboratory Manual. Cold Spring Harbor Laboratory Press.
- 27. Liu, Y., & Liu, Q. Hybridoma technology for the production of monoclonal antibodies. Nature Protocols, 2014; 9(11): 2540-2549.
- 28. Adams, G.P., & Weiner, L.M. Monoclonal antibody therapy of cancer. Nature Biotechnology, 2005; 23(9): 1147-1157.
- 29. Van Weemen, B. K., & Schuitemaker, H. The enzyme-linked immunosorbent assay. Journal of Immunological Methods, 1983; 57(1-2): 75-87.
- 30. Towbin, H., Staehelin, T., & Gordon, J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proceedings of the National Academy of Sciences, 1979; 76(9): 4350-4354.
- 31. Mason, D. Y. Immunofluorescence: A powerful tool in the diagnosis of autoimmune diseases. The Journal of Pathology, 1991; 165(2): 167-170.
- 32. Houssiau, F. A., & D'Cruz, D. Lupus: Pathogenesis and treatment. Rheumatology, 2016; 55(suppl_2): ii3-ii8.
- 33. Kelleher, A. D., & Carr, A. Antibody responses to HIV infection. Nature Reviews Immunology, 16(4), 201-218. Personalized cancer vaccines: Opportunities and challenges. Nature Reviews Drug Discovery, 2016; 17(5): 338-353.
- 34. Scott, A. M., & Wolchok, J. D. Antibody therapy of cancer. Nature Reviews Cancer, 2012; 12(4): 272-287.
- 35. Jansen, K. U., & de Dood, C. J. with bispecific antibodies. Molecular Immunology, 2018; 52(3-4): 123-129.
- 36. Kontermann, R. E. (2012). Dual targeting strategies.
- 37. De Vries, E., & Snijder, J. The role of antibody testing in the diagnosis of infectious diseases. Nature Reviews Microbiology, 2017; 15(1): 55-62.
- 38. Wild, D. (2013). The Immunoassay Handbook. Elsevier Science.
- 39. Zinsstag, J., Schelling, E., et al. (2006). Tuberculosis control in animals. World Health Organization.

- 40. Waters, W. R., et al. The use of interferon-gamma assays for diagnosis of tuberculosis in non-bovid species. Clinical and Vaccine Immunology, 2004; 11(7): 901-906.
- 41. Wood, P. R., et al. Enzyme-linked immunosorbent assay for the diagnosis of tuberculosis in animals. Australian Veterinary Journal, 1991; 68(8): 286-290.
- 42. Lyashchenko, K. P., et al. Fluorescent polarization assay for the detection of antibodies to Mycobacterium tuberculosis. Journal of Clinical Microbiology, 2000; 38(4): 1366-1371.
- 43. Parsons, L. M., et al. Laboratory diagnosis of tuberculosis in resource-poor countries: challenges and opportunities. Clinical Microbiology Reviews, 2011; 24(2): 314-350.
- 44. Greenwald, R., et al. Highly specific and sensitive multiple-antigen print immunoassay for serodiagnosis of tuberculosis in cattle. Clinical and Diagnostic Laboratory Immunology, 2003; 10(5): 704-709.
- 45. Figueroa, M. E., & Payton, M. A. The role of genetics in immunological disease. Nature Reviews Genetics, 2015; 16(1): 9-21.
- 46. Lanzavecchia, A., & Sallusto, F. Dynamics of T cell responses to antigens. Nature Reviews Immunology, 2000; 1(3): 221-228.
- 47. Miele, L., & Salerno, M. Diagnostic techniques in immunology: Antibody-based methods. Journal of Clinical Immunology, 2020; 40(7): 987-995.
- 48. Taylor, C. R. The utility of immunohistochemistry in clinical practice. Clinical Medicine & Research, 2003; 1(1): 6-13.
- 49. Aebersold, R., & Mann, M. Mass spectrometry-based proteomics. Nature, 2003; 422(6928): 198-207.
- 50. Boussiotis, V. A. T-cell dysfunction in the pathogenesis of autoimmune disease. Journal of Clinical Investigation, 2017; 127(1): 19-30.
- 51. Leventhal, J. R., & Ghosh, S. Immunological profiling for personalized medicine. Seminars in Immunology, 2016; 28(5): 309-314.
- 52. Smolen, J. S., & Aletaha, D. Disease activity in rheumatoid arthritis and its role in the management of disease. Nature Reviews Rheumatology, 2008; 4(9): 533-538.
- 53. Gans, H. A., & Murphy, C. A. The role of advanced molecular diagnostics in autoimmune disease management. Clinical Immunology, 2020; 215: 108470.
- 54. Choi, W. S., & Hwang, S. (2019). Predictive biomarkers in immunological diseases: The future of precision medicine.